Evista (raloxifene) can help prevent breast cancer in postmenopausal women with osteoporosis
February 2005
There's more evidence that Evista (raloxifene) can help prevent breast cancer in postmenopausal women with osteoporosis.
Evista is approved only to prevent or treat osteoporosis in postmenopausal women. But these women seem to have a 60% reduction in breast cancer while taking Evista.
But don't recommend Evista just to prevent breast cancer.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote